Beta-blockers Do Not Provide Protection From Colorectal Cancer

TOP - Daily - Colorectal Cancer

In recent years, researchers have considered a potential link between beta-blockers and a decreased risk of cancer. This theory stems from the fact that beta-blockers inhibit the actions of the stress hormone norepinephrine. This, along with studies that found norepinephrine can promote the growth and spread of cancer cells, led researchers to reason that the beta-blockers could have anticancer properties.

However, a recent study published early online in Cancer revealed that the use of beta-blockers showed no reduction of colorectal cancer risk.

To provide more thorough information on the effects of beta-blockers on colorectal cancer risk, Michael Hoffmeister, PhD, of the German Cancer Research Center in Heidelberg, Germany, and colleagues conducted interviews with 1762 patients with colorectal cancer and 1708 cancer-free individuals from 2003 to 2007.

The researchers found no link between beta-blocker use and colorectal cancer risk, even after taking into account patient characteristics like weight, smoking status, and other factors that might influence the results. In an evaluation of the analyses by duration of use of beta-blockers, specific types of beta-blockers, active ingredients (metoprolol, bisoprolol, carvedilol, and atenolol), and sites within the colon or rectum where colorectal cancer developed, researchers still did not discover a link. Therefore, study results do not support the suggestion that the use of beta-blockers can reduce colorectal cancer risk.

Source: Wiley-Blackwell.

Related Items
Adagrasib Shows Promising Activity in Patients with KRASᴳ¹²ᶜ-Mutated Metastatic Colorectal Cancer
Patricia Stewart
TOP - January 2022 Vol 15, No 1 – Online Only published on January 20, 2022 in Colorectal Cancer
Nivolumab plus Ipilimumab May Be a New First-Line Option for Patients with MSI-H or dMMR Metastatic Colorectal Cancer
William King
TOP - September 2020 Vol 13, No 5 published on September 14, 2020 in Colorectal Cancer
Pembrolizumab Doubles Progression-Free Survival in Subset of Patients with Metastatic Colorectal Cancer
Charlie Dawson
TOP - September 2020 Vol 13, No 5 published on September 14, 2020 in Colorectal Cancer
Encorafenib plus Cetuximab Improves Quality of Life versus Standard of Care in Colorectal Cancer Associated with BRAF Mutation
Wayne Kuznar
TOP - May 2020, Vol 13, No 3 published on May 21, 2020 in Colorectal Cancer
Immunotherapy Combination Extends Survival in Advanced Refractory Colorectal Cancer
Wayne Kuznar
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in Colorectal Cancer
Nivolumab Shows Durable Activity in Subgroups of Patients with Metastatic CRC
Charles Bankhead
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in Colorectal Cancer
Regorafenib Dose-Escalation Strategy Potentially a New Standard in Metastatic Colorectal Cancer
Wayne Kuznar
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in Colorectal Cancer
Evidence Supports the Use of Aspirin for Precision Chemoprevention of Colorectal Cancer
Meg Barbor, MPH
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Colorectal Cancer
Left- vs Right-Sided Colon Cancers
Eric Van Cutsem, MD, PhD
Videos published on July 25, 2017 in Colorectal Cancer, Video
Investigational Drug for Cachexia Appears to Improve Survival
Chase Doyle
TOP - May 2015, Vol 8, No 2 published on May 1, 2015 in Colorectal Cancer
Last modified: July 22, 2021